Transforming the Treatment Paradigm for Duchenne – Presented by Dyne Therapeutics

March 8, 2023 1:00PM

Join Jett Foundation’s Community Webinar Series on March 8 at 1PM ET as we welcome Dyne Therapeutics for a presentation and discussion on transforming the treatment paradigm for Duchenne muscular dystrophy.

Transforming the Treatment Paradigm for Duchenne
Wednesday, March 8, 2023
1:00PM ET | 12:00PM CT | 11AM MT | 10AM PT

Molly White, VP, Global Head of Patient Advocacy and KOL Engagement

Guest Speaker

Molly brings extensive experience in patient advocacy and community engagement to her role at Dyne. She previously served as chief executive officer of the Myotonic Dystrophy Foundation, a global patient advocacy organization. In that role, she led strategic direction and administrative oversight for the comprehensive programmatic and fundraising efforts of the foundation and its staff. Molly has over 25 years of leadership-level experience building, implementing, and running award-winning domestic and international community programs for organizations in both the private and nonprofit sectors. She has created partnerships with a range of governmental, nonprofit, and private sector stakeholders to launch initiatives targeting key national issues such as childhood obesity prevention and components of healthcare reform. She received her M.A. from the University of Iowa.

Ashish Dugar, PhD, MBA, Chief Medical Affairs Officer

Guest Speaker

Ash Dugar brings to Dyne over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. Prior to joining Dyne, Ash served as vice president and global head of medical affairs at Sarepta Therapeutics, Inc., where he built the company’s medical affairs organization. Previously, he led all commercial and market access efforts for Intra-Cellular Therapies, Inc. as vice president and head of commercial development. Ash joined Intra-Cellular Therapies following his tenure at Roche, where he was global head of clinical development science and innovation and global head of the external development group, including work in oligonucleotides.

Previously, he spent 13 years at Pfizer Inc. in various roles, most recently serving as vice president, global head of clinical development and medical affairs of the biosimilars business unit. Ash began his career at the National Institutes of Health. He completed a pharmacoeconomics and outcomes research fellowship at the University of Michigan School of Public Health. Ash earned an MBA from The Pennsylvania State University and a Ph.D. in pharmacology from The Pennsylvania State University College of Medicine.

Community Webinar Series - Better preparing for challenges in Duchenne

Our Community Webinar Series is focused on ensuring that our Duchenne community is better prepared for those unexpected moments, challenging medical decisions, and difficult stages when on a Duchenne journey.

No one ever expects Duchenne and there is no correct way to tackle a diagnosis, but we can always better prepare. This webinar series is an opportunity to equip yourself with more knowledge, resources, and tools for those real-life, often unanticipated, scenarios.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open